Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propylhexedrine is a small molecule sympathomimetic amine used primarily as an over-the-counter nasal decongestant. It acts as an alpha-adrenergic agonist, causing vasoconstriction in the nasal mucosa to relieve congestion associated with colds, allergies, and allergic rhinitis[1][2][3][4][5]. At therapeutic doses via inhalation, its main effect is local vasoconstriction; at higher or abused doses, it acts centrally as a norepinephrine–dopamine releasing agent (NDRA), increasing synaptic concentrations of norepinephrine and dopamine by reversing their transporters and antagonizing VMAT2[1][3][6]. Propylhexedrine was first introduced for medical use in 1949[3] and is marketed under the brand name Benzedrex. It has a low potential for abuse compared to other stimulants but can cause serious cardiovascular and psychiatric effects if misused[5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propylhexedrine.